GSTM1 and cancer: Erythropoiesis stimulating agents (ESAs) have been shown to increase Hb levels and reduce transfusion requirements in patients with cancer (Littlewood et al, 2001; Österborg et al, 2002; Vansteenkiste et al, 2002).